Tirzepatide Weight Management
Tirzepatide is a prescription medication that activates both GIP and GLP-1 receptors. It helps regulate appetite and food intake and can support weight reduction alongside nutrition, physical activity, and ongoing medical follow-up.
Treatment begins with a medical consultation to review your health history, current medications, suitability, contraindications and possible side effects.
Available weekly dose strengths
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
The initial tirzepatide dose is 2.5 mg. The dose may be adjusted after each four-week period based on weight-loss progress, tolerability, and medical evaluation. Dose increases are not automatic.
Medical consultation & laboratory evaluation
During the consultation, we may order basic laboratory tests to assess kidney function, liver function, thyroid function, blood glucose and a lipid (cholesterol) panel, based on clinical judgment.
Initial medical consultation
$100
We assess whether you are a candidate for treatment. Basic blood tests, when medically indicated, are included in the $100 consultation.
Starting dose: 2.5 mg
Starting at $300 per four-week period (initial 2.5 mg dose)
The initial medical consultation is $100. Treatment starts at $300 per four-week period for the initial 2.5 mg dose. Basic laboratory tests, if medically indicated, are included in the $100 initial consultation. Subsequent dosing and pricing are determined during medical follow-up.
Healthy Eating Guide
Simple meal ideas during weight management treatment
Menu 1 · Classic
Menu 2 · Variety
Healthy Snacks Between Meals
Illustrative plate-area proportions, not percentages of calories or macronutrients. Portions and snacks should be individualized. Patients with diabetes, kidney disease, or other medical conditions may need tailored guidance.
Possible side effects and contraindications
Common side effects
Nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion or heartburn, belching, fatigue, injection-site reactions, and sometimes hair loss. These symptoms may be more noticeable when treatment begins or the dose increases.
When tirzepatide must not be used
Do not use tirzepatide if you have a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN2), or a previous serious allergic reaction to tirzepatide or its ingredients.
Important precautions and serious risks
Medical evaluation is particularly important if you have a history of pancreatitis, gallbladder disease, kidney problems, severe digestive problems (including gastroparesis), or diabetes treated with insulin or sulfonylureas because of the risk of low blood sugar. Tirzepatide can cause dehydration-related kidney injury, gallbladder problems, pancreatitis, and severe allergic reactions. It is not recommended in severe gastroparesis.
Tirzepatide should not be used during pregnancy. Tell your clinician if you are pregnant, planning pregnancy, or breastfeeding. Oral contraceptives may be less effective: use a non-oral method or an additional barrier method for four weeks after starting treatment and for four weeks after each dose increase. Tell your anesthesia team before any surgery or deep sedation.
Seek urgent medical care for persistent severe abdominal pain, repeated vomiting with dehydration, facial or throat swelling, breathing difficulty, or other severe symptoms. Tirzepatide is prescription-only and requires individualized medical supervision.
Book a Consultation